161 related articles for article (PubMed ID: 1762088)
21. Clinical pharmacokinetics of levorotatory and racemic disopyramide, at steady state, following oral administration in patients with ventricular arrhythmias.
Le Corre P; Gibassier D; Descaves C; Sado P; Daubert JC; Le Verge R
J Clin Pharmacol; 1989 Dec; 29(12):1089-96. PubMed ID: 2482304
[TBL] [Abstract][Full Text] [Related]
22. Interspecies differences in stereoselective protein binding and clearance of MK-571.
Tocco DJ; deLuna FA; Duncan AE; Hsieh JH; Lin JH
Drug Metab Dispos; 1990; 18(4):388-92. PubMed ID: 1976057
[TBL] [Abstract][Full Text] [Related]
23. Stereospecific pharmacokinetics of free and protein-bound ketoprofen in serum and synovial fluid of horses after intravenous and intramuscular administration.
Brink P; DeGraves F; Ravis WR; Johansen D; Campbell JD; Duran SH
Am J Vet Res; 1998 Jun; 59(6):739-43. PubMed ID: 9622744
[TBL] [Abstract][Full Text] [Related]
24. Age and gender influence the stereoselective pharmacokinetics of propranolol.
Gilmore DA; Gal J; Gerber JG; Nies AS
J Pharmacol Exp Ther; 1992 Jun; 261(3):1181-6. PubMed ID: 1602383
[TBL] [Abstract][Full Text] [Related]
25. The pharmacokinetic and pharmacodynamic effects of varying the free fraction of disopyramide.
Shaw LM; Doherty JU; Waxman HL; Josephson ME
Angiology; 1987 Feb; 38(2 Pt 2):192-7. PubMed ID: 3826754
[TBL] [Abstract][Full Text] [Related]
26. Simultaneous determination of disopyramide and mono-N-dealkyldisopyramide enantiomers in plasma and urine by use of a chiral cellulose-derivative column.
Echizen H; Ochiai K; Kato Y; Chiba K; Ishizaki T
Clin Chem; 1990 Jul; 36(7):1300-4. PubMed ID: 2372941
[TBL] [Abstract][Full Text] [Related]
27. Pharmacokinetics of the enantiomers of verapamil in the dog.
Bai SA; Lankford SM; Johnson LM
Chirality; 1993; 5(6):436-42. PubMed ID: 8398603
[TBL] [Abstract][Full Text] [Related]
28. Direct enantiomeric resolution of disopyramide and its metabolite using chiral high-performance liquid chromatography. Application to stereoselective metabolism and pharmacokinetics of racemic disopyramide in man.
Le Corre P; Gibassier D; Sado P; Le Verge R
J Chromatogr; 1988 Oct; 450(2):211-6. PubMed ID: 3235589
[TBL] [Abstract][Full Text] [Related]
29. Accumulation of a disopyramide metabolite in renal failure.
Inagaki Y; Amano I; Otsu T
ASAIO J; 1993; 39(3):M609-13. PubMed ID: 8268610
[TBL] [Abstract][Full Text] [Related]
30. Plasma binding of disopyramide and mono-N-dealkyldisopyramide.
Bredesen JE; Pike E; Lunde PK
Br J Clin Pharmacol; 1982 Nov; 14(5):673-6. PubMed ID: 7138747
[TBL] [Abstract][Full Text] [Related]
31. Steady-state pharmacokinetics and bioavailability of total and unbound disopyramide in children with cardiac arrhythmias.
Chiba K; Koike K; Nakamoto M; Echizen H; Ishizawa A; Ishizaki T
Ther Drug Monit; 1992 Apr; 14(2):112-8. PubMed ID: 1585394
[TBL] [Abstract][Full Text] [Related]
32. Enantioselective steady-state kinetics of unbound disopyramide and its dealkylated metabolite in man.
Hasselström J; Enquist M; Hermansson J; Dahlqvist R
Eur J Clin Pharmacol; 1991; 41(5):481-4. PubMed ID: 1761078
[TBL] [Abstract][Full Text] [Related]
33. Population pharmacokinetics of prednisolone in children with acute lymphoblastic leukemia.
Petersen KB; Jusko WJ; Rasmussen M; Schmiegelow K
Cancer Chemother Pharmacol; 2003 Jun; 51(6):465-73. PubMed ID: 12698270
[TBL] [Abstract][Full Text] [Related]
34. Disopyramide concentrations in saliva.
Aitio ML; Virtanen R; Lammintausta R
Int J Clin Pharmacol Ther Toxicol; 1982 Feb; 20(2):68-72. PubMed ID: 7061181
[TBL] [Abstract][Full Text] [Related]
35. Hemodynamic and electrophysiologic effects of disopyramide enantiomers in a canine blood superfusion model.
Kidwell GA; Lima JJ; Schaal SF; Muir WW
J Cardiovasc Pharmacol; 1989 Apr; 13(4):644-55. PubMed ID: 2471004
[TBL] [Abstract][Full Text] [Related]
36. Pharmacokinetics of thiamylal enantiomers in humans.
Sueyasu M; Ikeda T; Taniyama T; Futugami K; Kataoka Y; Oishi R
Int J Clin Pharmacol Ther; 1997 Mar; 35(3):128-32. PubMed ID: 9089003
[TBL] [Abstract][Full Text] [Related]
37. Stereoselective pharmacokinetics of L-buthionine SR-sulfoximine in patients with cancer.
Lacreta FP; Brennan JM; Hamilton TC; Ozols RF; O'Dwyer PJ
Drug Metab Dispos; 1994; 22(6):835-42. PubMed ID: 7895599
[TBL] [Abstract][Full Text] [Related]
38. The pharmacokinetics of disopyramide and mono-N-dealkyl-disopyramide in humans.
Aitio ML; Allonen H; Kanto J; Mäntylä R
Int J Clin Pharmacol Ther Toxicol; 1982 May; 20(5):219-26. PubMed ID: 7095921
[TBL] [Abstract][Full Text] [Related]
39. A simple method for the simulation of unbound serum disopyramide concentration in patients.
Kishino S; Kohri N; Iseki K; Miyazaki K; Nomura A; Yasuda H
J Pharmacobiodyn; 1991 Sep; 14(9):493-9. PubMed ID: 1779403
[TBL] [Abstract][Full Text] [Related]
40. [Accumulation of a disopyramide metabolite in renal failure].
Otsu T; Ito T; Inagaki Y; Amano I; Masamoto S; Niwa M
Nihon Jinzo Gakkai Shi; 1993 Sep; 35(9):1065-71. PubMed ID: 8230817
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
